It is the question behind every fat grafting consultation after breast cancer: could transferring fat wake the cancer up? The concern is rational. Fat grafts carry adipose-derived stem cells and growth factors, and laboratory studies show these can stimulate cell growth in vitro. What matters clinically, though, is what happens in patients, and that question has now been studied in tens of thousands of them. This article summarises the oncological evidence on autologous fat grafting (lipofilling) after breast cancer, in plain language, with the sources named.
Where the worry comes from
In the laboratory, adipose-derived stem cells can promote proliferation and angiogenesis, and early experimental work raised the possibility that a grafted, growth-factor-rich environment might encourage residual tumour cells. This is why fat grafting after cancer was approached cautiously, why registries and matched studies were set up, and why the question deserves a serious answer rather than reassurance by assertion.
What the clinical evidence shows
Across the major syntheses, the clinical signal is consistent: no measurable increase in recurrence after fat grafting in reconstructed breasts.
- A meta-analysis of matched and cohort studies in the British Journal of Surgery (Krastev et al., 2018) compared thousands of grafted patients with controls and found no significant difference in locoregional recurrence.
- A systematic review and meta-analysis in BMC Cancer (2022), pooling over 20 studies, likewise reported no increase in local, regional or distant recurrence with lipofilling after breast cancer surgery.
- Large single-institution matched-cohort studies with long follow-up, including case-control series in surgical oncology journals through 2024, continue to report recurrence rates in grafted patients comparable to non-grafted controls.
Guidance from professional societies reflects this: fat grafting after breast cancer treatment is considered oncologically acceptable, with the usual insistence on completed oncological treatment, multidisciplinary oversight and follow-up imaging awareness.
The caveats that honest counselling includes
- The evidence is observational. There is no large randomised trial, and matched cohorts can hide selection effects; the consistency across many independent datasets is what gives the conclusion its weight.
- Imaging changes are real but manageable. Grafted fat can form oil cysts and calcifications. Radiologists familiar with post-grafting appearances distinguish these from suspicious findings, and studies report no meaningful delay in cancer detection, but the surveillance team should always know grafting has occurred.
- Subgroups are studied less. Data in very young patients, high-risk genetic carriers and specific tumour biologies are thinner, and individualised multidisciplinary advice matters most exactly there.
What this means in reconstruction
The reassuring evidence base is why fat grafting has moved to the centre of modern reconstruction: refining implant-based results, enabling hybrid reconstruction, softening irradiated tissue, and rebuilding contour after conserving surgery. Technique still matters, from processing quality (see our fat dialysis guide) to recipient-site preparation with rigottomia in scarred beds. Oncological safety is a property of the whole pathway: completed treatment, informed surveillance and good surgical technique together.
The bottom line
The laboratory concern was legitimate; the clinical answer, accumulated across meta-analyses and matched cohorts covering thousands of patients, is that fat grafting after breast cancer has not been shown to increase recurrence. Patients should hear both halves of that sentence, along with the caveats, from a team that knows their individual disease. That is what informed consent sounds like.
Key published sources
- Krastev TK, et al. Meta-analysis of the oncological safety of autologous fat transfer after breast cancer. British Journal of Surgery. 2018.
- The oncological safety of autologous fat grafting: a systematic review and meta-analysis. BMC Cancer. 2022.
- Oncologic safety of autologous fat grafting in primary breast reconstruction after mastectomy for cancer, matched case-control studies through 2024, surgical oncology literature.
- Petit JY, et al. Institutional lipofilling registry analyses, European Institute of Oncology series.
Important information This article is general education, not medical advice. Tap to read the full medical, regulatory & legal notice.
This article is provided by Advanced Biomedical Concept for general informational and educational purposes only. It does not constitute medical, surgical, diagnostic, or other professional healthcare advice, and it is not a substitute for consultation with a suitably qualified healthcare professional. Reading it creates no doctor–patient or other professional relationship. Nothing here should be used to diagnose, treat, cure, or prevent any disease or condition, or to make decisions about medical care. Always seek the advice of a physician or other qualified provider with any questions about a medical condition or treatment, and never disregard or delay professional advice because of something you have read here.
Any reference to Advanced Biomedical Concept products (including ExaShape and ExaFat) is provided for general information only. These are medical devices intended to be used by appropriately trained healthcare professionals strictly in accordance with their applicable, current Instructions for Use (IFU). Regulatory status (including CE marking and classification under the EU Medical Device Regulation), market availability, and approved indications differ between countries and may change over time; a device referred to here may not be available or approved in your country. This content is not intended as, and must not be relied upon as, a statement or claim of safety, clinical performance, or efficacy beyond what is set out in the applicable IFU and current regulatory approvals. Product-specific information is directed at healthcare professionals and is not intended to promote, advertise, or offer any medical device to the general public where such promotion is restricted or prohibited by law.
Statements reflect information believed to be accurate at the date of publication and may be updated or corrected without notice. Any statements regarding the future are expectations or general views, not guarantees. Clinical outcomes depend on many individual factors, results vary from person to person, and no particular result is promised or implied. Where third-party studies, sources, or external links are referenced, they are provided for convenience and information only and do not imply endorsement, and Advanced Biomedical Concept is not responsible for their content.
To the fullest extent permitted by applicable law, Advanced Biomedical Concept and its officers, employees, contributors, and representatives (each acting in that capacity and on behalf of Advanced Biomedical Concept) accept no liability for any loss, injury, or damage of any kind arising directly or indirectly from use of, or reliance on, this content. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Questions about this material can be directed to us via our contact page.
Last reviewed: August 24, 2026.